136 related articles for article (PubMed ID: 16511428)
1. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
Kelleher AD; Puls RL; Bebbington M; Boyle D; Ffrench R; Kent SJ; Kippax S; Purcell DF; Thomson S; Wand H; Cooper DA; Emery S
AIDS; 2006 Jan; 20(2):294-7. PubMed ID: 16511428
[TBL] [Abstract][Full Text] [Related]
2. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques.
De Rose R; Chea S; Dale CJ; Reece J; Fernandez CS; Wilson KM; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Sullivan MT; Kent SJ
Vaccine; 2005 Mar; 23(16):1949-56. PubMed ID: 15734067
[TBL] [Abstract][Full Text] [Related]
3. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells.
Radaelli A; Bonduelle O; Beggio P; Mahe B; Pozzi E; Elli V; Paganini M; Zanotto C; De Giuli Morghen C; Combadière B
Vaccine; 2007 Mar; 25(11):2128-38. PubMed ID: 17241705
[TBL] [Abstract][Full Text] [Related]
4. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
5. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
Hemachandra A; Puls RL; Sirivichayakul S; Kerr S; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher A; Ruxrungtham K
Hum Vaccin; 2010 Oct; 6(10):835-40. PubMed ID: 20864808
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.
Ranasinghe C; Medveczky JC; Woltring D; Gao K; Thomson S; Coupar BE; Boyle DB; Ramsay AJ; Ramshaw IA
Vaccine; 2006 Jul; 24(31-32):5881-95. PubMed ID: 16759767
[TBL] [Abstract][Full Text] [Related]
7. Comparison of whole gene and whole virus scrambled antigen approaches for DNA prime and fowlpox virus boost HIV type 1 vaccine regimens in macaques.
Pamungkas J; De Rose R; Iskandriati D; Noviana R; Paramastri Y; Dale CJ; Shoobridge M; Medveczky CJ; Ramshaw IA; Thomson S; Kent SJ
AIDS Res Hum Retroviruses; 2005 Apr; 21(4):292-300. PubMed ID: 15943571
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
Gorse GJ; Baden LR; Wecker M; Newman MJ; Ferrari G; Weinhold KJ; Livingston BD; Villafana TL; Li H; Noonan E; Russell ND;
Vaccine; 2008 Jan; 26(2):215-23. PubMed ID: 18055072
[TBL] [Abstract][Full Text] [Related]
9. Prime-boost strategies in DNA vaccines.
Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
[TBL] [Abstract][Full Text] [Related]
10. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
[TBL] [Abstract][Full Text] [Related]
11. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
Ramanathan VD; Kumar M; Mahalingam J; Sathyamoorthy P; Narayanan PR; Solomon S; Panicali D; Chakrabarty S; Cox J; Sayeed E; Ackland J; Verlinde C; Vooijs D; Loughran K; Barin B; Lombardo A; Gilmour J; Stevens G; Smith MS; Tarragona-Fiol T; Hayes P; Kochhar S; Excler JL; Fast P
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1107-16. PubMed ID: 19943789
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers.
McFarland EJ; Johnson DC; Muresan P; Fenton T; Tomaras GD; McNamara J; Read JS; Douglas SD; Deville J; Gurwith M; Gurunathan S; Lambert JS
AIDS; 2006 Jul; 20(11):1481-9. PubMed ID: 16847402
[TBL] [Abstract][Full Text] [Related]
13. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials.
Coupar BE; Purcell DF; Thomson SA; Ramshaw IA; Kent SJ; Boyle DB
Vaccine; 2006 Feb; 24(9):1378-88. PubMed ID: 16257479
[TBL] [Abstract][Full Text] [Related]
14. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.
Mulligan MJ; Russell ND; Celum C; Kahn J; Noonan E; Montefiori DC; Ferrari G; Weinhold KJ; Smith JM; Amara RR; Robinson HL;
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):678-83. PubMed ID: 16831092
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.
Mehendale S; van Lunzen J; Clumeck N; Rockstroh J; Vets E; Johnson PR; Anklesaria P; Barin B; Boaz M; Kochhar S; Lehrman J; Schmidt C; Peeters M; Schwarze-Zander C; Kabamba K; Glaunsinger T; Sahay S; Thakar M; Paranjape R; Gilmour J; Excler JL; Fast P; Heald AE
AIDS Res Hum Retroviruses; 2008 Jun; 24(6):873-80. PubMed ID: 18544020
[TBL] [Abstract][Full Text] [Related]
16. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.
Asmuth DM; Brown EL; DiNubile MJ; Sun X; del Rio C; Harro C; Keefer MC; Kublin JG; Dubey SA; Kierstead LS; Casimiro DR; Shiver JW; Robertson MN; Quirk EK; Mehrotra DV
J Infect Dis; 2010 Jan; 201(1):132-41. PubMed ID: 19929694
[TBL] [Abstract][Full Text] [Related]
17. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
[TBL] [Abstract][Full Text] [Related]
18. The preventive phase I trial with the HIV-1 Tat-based vaccine.
Ensoli B; Fiorelli V; Ensoli F; Lazzarin A; Visintini R; Narciso P; Di Carlo A; Tripiciano A; Longo O; Bellino S; Francavilla V; Paniccia G; Arancio A; Scoglio A; Collacchi B; Ruiz Alvarez MJ; Tambussi G; Tassan Din C; Palamara G; Latini A; Antinori A; D'Offizi G; Giuliani M; Giulianelli M; Carta M; Monini P; Magnani M; Garaci E
Vaccine; 2009 Dec; 28(2):371-8. PubMed ID: 19879233
[TBL] [Abstract][Full Text] [Related]
19. [Construction of recombinant fowlpox virus coexpressing gp120 of Chinese HIV-1 strain and IL-18 and its immunogenicity in mice].
Jiang WZ; Jin NY; Li ZJ; Zhang LS; Han WY
Sheng Wu Gong Cheng Xue Bao; 2004 May; 20(3):337-41. PubMed ID: 15971601
[TBL] [Abstract][Full Text] [Related]
20. Construction and characterization of recombinant fowlpox virus coexpressing HIV-1(CN) gp120 and IL-2.
Jiang W; Jin N; Cui S; Li Z; Zhang L; Zhang H; Wang H; Han W
J Virol Methods; 2005 Dec; 130(1-2):95-101. PubMed ID: 16029899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
